BioSpace News Archive

Analysis for the co-primary endpoint of objective response rate and an interim analysis of progression-free survival expected in the second half of 2020

Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI; OTCQX:NRIFF), a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three and twelve months ended December 31, 2019.

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today reported financial results for the full year ended December 31, 2019.

Entrada Therapeutics, Inc., a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases through the development of intracellular biologics, today announced that Dipal Doshi, President and Chief Executive Officer, will present at the Cowen and Company 40th Annual Healthcare Conference in Boston on Monday, March 2, 2020 at 9:30 a.m. Eastern Standard Time.

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate update at the Cowen 40th Annual Health Care Conference, taking place March 2-4, 2020 in Boston, Massachusetts.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2019 financial results will be released on Thursday, March 5, 2020 before the U.S. financial markets open.

Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced it has entered into convertible note extension agreements and lock-up agreements with certain institutional investors who participated in the Company’s previously announced $1.35M financing round in Q1 2019 (the ‘2019 Bridge Financing’).

Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore the co-administration of SB 11285, Spring Bank’s intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced solid tumors.

NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present an overview of the company and a business update at the Cowen and Company 40th Annual Health Care Conference in Boston on Monday, March 2, at 2:10 p.m. ET.

Atrin Pharmaceuticals, a private biopharmaceutical company pioneering the discovery and development of proprietary molecules targeting DNA Damage and Repair (DDR) pathways to treat cancers that currently do not have effective therapies, today reported preliminary results from a collaborative genomics analysis that will be used to optimize patient selection for Atrin’s upcoming ATRN-119 clinical trial.